Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Skinvisible (SKVI) Accumulated Expenses (2016 - 2025)

Skinvisible (SKVI) has disclosed Accumulated Expenses for 16 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 20.55% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, up 20.55% year-over-year, with the annual reading at $3.4 million for FY2025, 20.55% up from the prior year.
  • Accumulated Expenses hit $3.4 million in Q4 2025 for Skinvisible, up from $3.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $3.4 million in Q4 2025 to a low of $1.1 million in Q1 2021.
  • Historically, Accumulated Expenses has averaged $2.3 million across 5 years, with a median of $2.3 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: surged 81.99% in 2021 and later grew 6.83% in 2025.
  • Year by year, Accumulated Expenses stood at $1.5 million in 2021, then skyrocketed by 32.59% to $2.0 million in 2022, then skyrocketed by 31.69% to $2.6 million in 2023, then increased by 8.13% to $2.8 million in 2024, then rose by 20.55% to $3.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for SKVI at $3.4 million in Q4 2025, $3.2 million in Q3 2025, and $3.1 million in Q2 2025.